Literature DB >> 21738213

Eμ/miR-125b transgenic mice develop lethal B-cell malignancies.

Y Enomoto1, J Kitaura, K Hatakeyama, J Watanuki, T Akasaka, N Kato, M Shimanuki, K Nishimura, M Takahashi, M Taniwaki, C Haferlach, R Siebert, M J S Dyer, N Asou, H Aburatani, H Nakakuma, T Kitamura, T Sonoki.   

Abstract

MicroRNA-125b-1 (miR-125b-1) is a target of a chromosomal translocation t(11;14)(q24;q32) recurrently found in human B-cell precursor acute lymphoblastic leukemia (BCP-ALL). This translocation results in overexpression of miR-125b controlled by immunoglobulin heavy chain gene (IGH) regulatory elements. In addition, we found that six out of twenty-one BCP-ALL patients without t(11;14)(q24;q32) showed overexpression of miR-125b. Interestingly, four out of nine patients with BCR/ABL-positive BCP-ALL and one patient with B-cell lymphoid crisis that had progressed from chronic myelogenous leukemia overexpressed miR-125b. To examine the role of the deregulated expression of miR-125b in the development of B-cell tumor in vivo, we generated transgenic mice mimicking the t(11;14)(q24;q32) (Eμ/miR-125b-TG mice). Eμ/miR-125b-TG mice overexpressed miR-125b driven by IGH enhancer and promoter and developed IgM-negative or IgM-positive lethal B-cell malignancies with clonal proliferation. B cells obtained from the Eμ/miR-125b-TG mice were resistant to apoptosis induced by serum starvation. We identified Trp53inp1, a pro-apoptotic gene induced by cell stress, as a novel target gene of miR-125b in hematopoietic cells in vitro and in vivo. Our results provide direct evidence that miR-125b has important roles in the tumorigenesis of precursor B cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21738213     DOI: 10.1038/leu.2011.166

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  44 in total

1.  The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state.

Authors:  Esmerina Tili; Jean-Jacques Michaille; Zhenghua Luo; Stefano Volinia; Laura Z Rassenti; Thomas J Kipps; Carlo M Croce
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

Review 2.  MicroRNAs as therapeutic targets in human cancers.

Authors:  Maitri Y Shah; George A Calin
Journal:  Wiley Interdiscip Rev RNA       Date:  2014-03-28       Impact factor: 9.957

3.  Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis.

Authors:  Kebria Hezaveh; Andreas Kloetgen; Stephan H Bernhart; Kunal Das Mahapatra; Dido Lenze; Julia Richter; Andrea Haake; Anke K Bergmann; Benedikt Brors; Birgit Burkhardt; Alexander Claviez; Hans G Drexler; Roland Eils; Siegfried Haas; Steve Hoffmann; Dennis Karsch; Wolfram Klapper; Kortine Kleinheinz; Jan Korbel; Helene Kretzmer; Markus Kreuz; Ralf Küppers; Chris Lawerenz; Ellen Leich; Markus Loeffler; Luisa Mantovani-Loeffler; Cristina López; Alice C McHardy; Peter Möller; Marius Rohde; Philip Rosenstiel; Andreas Rosenwald; Markus Schilhabel; Matthias Schlesner; Ingrid Scholz; Peter F Stadler; Stephan Stilgenbauer; Stéphanie Sungalee; Monika Szczepanowski; Lorenz Trümper; Marc A Weniger; Reiner Siebert; Arndt Borkhardt; Michael Hummel; Jessica I Hoell
Journal:  Haematologica       Date:  2016-07-06       Impact factor: 9.941

Review 4.  Dysfunction of the TP53 tumor suppressor gene in lymphoid malignancies.

Authors:  Zijun Y Xu-Monette; L Jeffrey Medeiros; Yong Li; Robert Z Orlowski; Michael Andreeff; Carlos E Bueso-Ramos; Timothy C Greiner; Timothy J McDonnell; Ken H Young
Journal:  Blood       Date:  2012-01-24       Impact factor: 22.113

5.  Oncomir miR-125b regulates hematopoiesis by targeting the gene Lin28A.

Authors:  Aadel A Chaudhuri; Alex Yick-Lun So; Arnav Mehta; Aarathi Minisandram; Nikita Sinha; Vanessa D Jonsson; Dinesh S Rao; Ryan M O'Connell; David Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-24       Impact factor: 11.205

6.  Targeted therapies through microRNAs: pulp or fiction?

Authors:  Christian Langer; Frank G Rücker; Christian Buske; Hartmut Döhner; Florian Kuchenbauer
Journal:  Ther Adv Hematol       Date:  2012-04

7.  Epigenetic silencing of miR-125b is required for normal B-cell development.

Authors:  Guideng Li; Alex Yick-Lun So; Reeshelle Sookram; Stephanie Wong; Jessica K Wang; Yong Ouyang; Peng He; Yapeng Su; Rafael Casellas; David Baltimore
Journal:  Blood       Date:  2018-03-19       Impact factor: 22.113

8.  Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations.

Authors:  Daichi Inoue; Jiro Kitaura; Katsuhiro Togami; Koutarou Nishimura; Yutaka Enomoto; Tomoyuki Uchida; Yuki Kagiyama; Kimihito Cojin Kawabata; Fumio Nakahara; Kumi Izawa; Toshihiko Oki; Akie Maehara; Masamichi Isobe; Akiho Tsuchiya; Yuka Harada; Hironori Harada; Takahiro Ochiya; Hiroyuki Aburatani; Hiroshi Kimura; Felicitas Thol; Michael Heuser; Ross L Levine; Omar Abdel-Wahab; Toshio Kitamura
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

Review 9.  MicroRNAs: history, biogenesis, and their evolving role in animal development and disease.

Authors:  M Bhaskaran; M Mohan
Journal:  Vet Pathol       Date:  2013-09-17       Impact factor: 2.221

10.  MicroRNA-125b-1 accelerates a C-terminal mutant of C/EBPα (C/EBPα-C(m))-induced myeloid leukemia.

Authors:  Yutaka Enomoto; Jiro Kitaura; Masaya Shimanuki; Naoko Kato; Koutarou Nishimura; Mariko Takahashi; Hideki Nakakuma; Toshio Kitamura; Takashi Sonoki
Journal:  Int J Hematol       Date:  2012-07-28       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.